Figure 4.

Bemarituzumab decreases FGFR2 signaling in SNU-16 tumor-bearing mice. Western blot analyses of pan-phosphorylated FGFR (phospho-FGFR), total FGFR2b, phosphorylated FRS2 (phospho-FRS2), and total FRS2 in tumors from SNU-16 tumor-bearing mice are shown. All results were compared to a common housekeeping enzyme (GAPDH). a: Tumors from mice treated with a single IV dose of bemarituzumab (10 mg/kg) were collected at 2, 6, 24, and 72 hours post treatment (n = 3 per time point). Control groups included tumors collected at 2 hours from naive animals (n = 2) and at 24 hours post IgG treatment (10 mg/kg; n = 3). Bemarituzumab decreased phospho-FGFR and phospho-FRS2 within 2 hours, and decreased total FGFR2b levels within 6 hours. b: Tumors from mice treated with twice weekly IP doses of 10 mg/kg bemarituzumab or albumin were collected at 82 days post first bemarituzumab/albumin treatment (n = 3 per group). Compared with the albumin control group, bemarituzumab decreased phospho-FGFR, phospho-FRS2, and total FGFR2b levels